MGMT and glioblastoma: Recent studies have linked low DNMT1 expression with TMZ resistance, suggesting that alterations in DNA methylation may serve as indicators of treatment efficacy.113 Emerging research has also identified methylation patterns in DNA damage response (DDR) genes, including MGMT, MLH3, RAD21, and SMC4, as potential biomarkers for therapy response prediction.114 Findings from the EORTC 22033 phase III trial further underscore the clinical relevance of molecular stratification in GBM treatment.